The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The <scp>SEESAW</scp> randomized, double‐blind, placebo‐controlled trial

Jack A. Sargeant, James A. King, Thomas Yates, Emma L. Redman, Danielle H. Bodicoat, Sudesna Chatterjee, Charlotte L. Edwardson, Laura J. Gray, Benoit Poulin, Ghazala Waheed,

Diabetes Obesity and Metabolism · 2022 · 25 citations · 29 references

DOIFull text

Open access

Abstract

gov; 2015-001594-40, www.EudraCT.ema.europa.eu; ISRCTN82062639, www.ISRCTN.org.

References

29